Overview

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-03-29
Target enrollment:
Participant gender:
Summary
Phase I study designed to characterize the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous (s.c.) injection of pelacarsen in participants with mild hepatic impairment (HI) compared to matched healthy participants. This study will assess whether mild HI may affect the PK of pelacarsen.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals